Anna Bioscience

Anna Biosciences is a drug discovery company that uses decentralized partnerships to develop and advance new therapies for better patient outcomes. Anna Biosciences’ first initiative, the Syntem Platform, is developing proprietary molecules to create synthetic immunity. Its initial efforts are focused on virology, immuno-oncology, and neurodegenerative diseases. The platform’s multi-specific molecules first target and flag the pathology, and then elicit an immune reaction that targets the virus or disease. The Syntem Platform’s proprietary molecules and treatments have the potential to yield numerous advantages including: — Targeted therapies with minimal side effects — Ease of administration to patients — Ease of production — Lower overall treatment costs The first application of the platform is as a therapy to treat and prevent COVID-19. In addition, the company is currently working on the implementation of this approach to activate immune cells that can recognize and attack cancers.